GE HealthCare Technologies Inc. (NASDAQ:GEHC) Receives $94.09 Consensus Price Target from Brokerages

GE HealthCare Technologies Inc. (NASDAQ:GEHC) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $94.09.

A number of equities research analysts have commented on GEHC shares. Argus raised their price objective on GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Mizuho reduced their price objective on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Evercore ISI raised their price objective on GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Citigroup lifted their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, The Goldman Sachs Group began coverage on GE HealthCare Technologies in a research report on Thursday, May 30th. They set a “neutral” rating and a $87.00 target price on the stock.

GE HealthCare Technologies Trading Up 0.9 %

Shares of GEHC stock opened at $78.27 on Monday. The company has a market cap of $35.73 billion, a P/E ratio of 22.89, a PEG ratio of 2.79 and a beta of 1.22. The stock has a 50 day simple moving average of $80.99 and a two-hundred day simple moving average of $81.35. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06. GE HealthCare Technologies has a fifty-two week low of $62.35 and a fifty-two week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, meeting analysts’ consensus estimates of $0.90. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The firm had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same quarter last year, the firm posted $0.85 earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Research analysts forecast that GE HealthCare Technologies will post 4.27 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 15th. Investors of record on Friday, April 19th were issued a dividend of $0.03 per share. The ex-dividend date was Thursday, April 18th. This represents a $0.12 dividend on an annualized basis and a yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.51%.

Insider Buying and Selling

In other GE HealthCare Technologies news, insider Frank R. Jimenez purchased 1,315 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were acquired at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the completion of the acquisition, the insider now owns 75,796 shares of the company’s stock, valued at approximately $5,799,909.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Jan Makela sold 20,227 shares of GE HealthCare Technologies stock in a transaction on Monday, May 13th. The stock was sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the sale, the chief executive officer now directly owns 63,348 shares in the company, valued at $5,167,296.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Frank R. Jimenez bought 1,315 shares of the stock in a transaction on Wednesday, May 1st. The stock was purchased at an average price of $76.52 per share, for a total transaction of $100,623.80. Following the completion of the purchase, the insider now owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 90,482 shares of company stock worth $7,369,137. 0.27% of the stock is owned by company insiders.

Institutional Trading of GE HealthCare Technologies

Hedge funds have recently made changes to their positions in the company. Pathway Financial Advisers LLC bought a new stake in shares of GE HealthCare Technologies in the first quarter valued at $25,000. BNP Paribas bought a new stake in shares of GE HealthCare Technologies in the first quarter valued at $30,000. Rise Advisors LLC raised its stake in shares of GE HealthCare Technologies by 241.4% in the first quarter. Rise Advisors LLC now owns 338 shares of the company’s stock valued at $31,000 after buying an additional 239 shares during the period. Riverview Trust Co bought a new stake in shares of GE HealthCare Technologies in the first quarter valued at $31,000. Finally, Annapolis Financial Services LLC raised its stake in shares of GE HealthCare Technologies by 171.9% in the first quarter. Annapolis Financial Services LLC now owns 348 shares of the company’s stock valued at $32,000 after buying an additional 220 shares during the period. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.